Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Codrituzumab - Chugai Pharmaceutical/Roche

Drug Profile

Codrituzumab - Chugai Pharmaceutical/Roche

Alternative Names: GC-33; RG-7686; RO-5137382

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Perseus Proteomics
  • Developer Chugai Pharmaceutical; Roche
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Glypican 3 inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I Solid tumours

Most Recent Events

  • 23 May 2022 Codrituzumab is still in phase I trials for Liver cancer (Combination therapy, Late-stage disease, Metastatic disease) in Japan and Taiwan (IV) (JapicCTI-163325)
  • 27 Apr 2022 Phase II development is ongoing in Liver cancer (Roche pipeline, April 2022 )
  • 09 Jun 2021 Phase-I clinical trials in Solid tumours (In children, In adults, In adolescents, In infants, Second-line therapy or greater) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top